Nevertheless, a proportion of HER-2 amplified breast cancers continue to eventually develop drug resistance, probably due to the PTEN (phosphatase and tensin homolog) loss or activation of PIK3CA mutation (110). Here, PIK3CA is linked to breast carcinoma.